Please login to the form below

Not currently logged in
Email:
Password:

Novartis in health technology assessment trial with NICE

Novartis is collaborating with the UK's medicines agency, the National Institute of Health and Clinical Excellence on the joint design of a late-stage clinical trial to assess efficacy and health economics of a new drug

According to the UK newspaper The Financial Times, Swiss-headquartered Novartis has collaborated with the UK's medicines agency, the National Institute of Health and Clinical Excellence (NICE) on the joint design of a late-stage clinical trial.

According to the 17 December article, NICE will charge a fee for informing Novartis which criteria will form the basis of its decision to advise the NHS whether to buy the medicine once it is launched.

In an interview with the FT, Joe Jimenez, Novartis' head of pharmaceuticals, said: "This is about identifying the impact of the drug and the evidence of impact. Input at an early stage gives us the evidence to speed our drug to market. We're looking at more innovative ways to stand behind our drugs."

In November 2007, Novartis consulted with NICE on the design of the phase III trial for the drug, which is currently named Novartis 001.

According to the FT, the results of the trial are expected within a year.

19th December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...

Infographics